1
|
Yerushalmi GM, Avraham S, Kedem A, Youngster M, Barkat J, Baruchin O, Gat I, Yaakov O, Gidoni Y, Hourvitz A. GnRH agonist early follicular challenge test as a predictor of ovarian response in antagonist cycles for fertility preservation. Sci Rep 2024; 14:14308. [PMID: 38906914 PMCID: PMC11192755 DOI: 10.1038/s41598-024-65059-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Accepted: 06/17/2024] [Indexed: 06/23/2024] Open
Abstract
The aim of our study was to evaluate if the response to follicular GnRH agonist (GnRHa) trigger be used to predict intracycle ovarian response in GnRH antagonist cycles among women undergoing fertility preservation IVF. We conducted a prospective study of 146 GnRH antagonist oocyte pickup (OPU) cycles to evaluate GnRHa stimulation test (GAST). On day 2 of the cycle, basal E2 were measured, followed by injection of 0.2 mg GnRHa as part of the initial ovarian stimulation. 12 h later blood sampling was repeated (GAST E3). E2 response was used as test parameter. The major outcome was the number of mature cryopreserved oocytes. We found a linear correlation between both GAST E3 level and GAST E3/E2 ratio and number of M2 oocytes. ROC curve analysis of GAST E3, GAST E3/E2 ratio, AFC and day 3 FSH for > 15 M2 and < 5 M2 oocytes was calculated. For GAST E3 levels obtaining < 5 M2 oocytes, an AUC value of 0.79 was found. For GAST E3 levels obtaining > 15 M2 oocytes, AUC value of 0.8. Patients with GAST E3 ≤ 384 pmol/l has 58.6% risk to obtain < 5 oocytes. Patients younger than 35 with GAST E3 > 708 pmol/l have 66% chance for freezing > 15 oocytes. The response to single GnRHa administration during GnRH antagonist cycle can be used as biomarker of ovarian reserve. This simple, widely available marker, which reflect the estradiol response of small follicles, might predict the response of the specific cycle, and can potentially be used to adjust the treatment dose.Trial registration number: 0304-20-ASF.
Collapse
Affiliation(s)
- Gil M Yerushalmi
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel.
| | - Sarit Avraham
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Alon Kedem
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Michal Youngster
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Jonathan Barkat
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Ohad Baruchin
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Itai Gat
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Odelia Yaakov
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Yariv Gidoni
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| | - Ariel Hourvitz
- IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Centre, Tzrifin, affiliated with the Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
- Alan and Ada Selwyn Chair for Clinical Infertility Research and Molecular Medicine, Faculty of Medical and Health Science, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
2
|
Fertility 2007 Biennial Joint Meeting of the UK Fertility Societies, University of York, April 15 – 18, 2007. HUM FERTIL 2009. [DOI: 10.1080/14647270701683186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Coppus SFPJ, van der Veen F, Bossuyt PMM, Mol BWJ. Quality of reporting of test accuracy studies in reproductive medicine: impact of the Standards for Reporting of Diagnostic Accuracy (STARD) initiative. Fertil Steril 2006; 86:1321-9. [PMID: 16978620 DOI: 10.1016/j.fertnstert.2006.03.050] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2005] [Revised: 03/28/2006] [Accepted: 03/28/2006] [Indexed: 11/28/2022]
Abstract
OBJECTIVE To evaluate the extent to which test accuracy studies published in two leading reproductive medicine journals in the years 1999 and 2004 adhered to the Standards for Reporting of Diagnostic Accuracy (STARD) initiative parameters, and to explore whether the introduction of the STARD statement has led to an improved quality of reporting. DESIGN Structured literature search. Articles that reported on the diagnostic performance of a test in comparison with a reference standard were eligible for inclusion. For each article we scored how well the 25 items of the STARD checklist were reported. These items deal with the study question, study participants, study design, test methods, reference standard, statistical methods, reporting of results, and conclusions. We calculated the total number of reported STARD items per article, summary scores for each STARD item, and the average number of reported STARD items per publication year. SETTING Not applicable. PATIENT(S) Not applicable. INTERVENTION(S) Not applicable. MAIN OUTCOME MEASURE(S) Quality of reporting. RESULT(S) We found 24 studies reporting on test accuracy in reproductive medicine in 1999 and 27 studies in 2004. The mean number of reported STARD items for articles published in 1999 was 12.1 +/- 3.3 (range 6.5-20) and 12.4 +/- 3.2 (range 7-17.5) in 2004, after publication of the STARD statement. Overall, less than half of the studies reported adequately on 50% or more of the STARD items. The reporting of individual items showed a wide variation. There was no significant improvement in mean number of reported items for the articles published after the introduction of the STARD statement. CONCLUSION(S) Authors of test accuracy studies in the two leading fertility journals poorly report the design, conduct, methodology, and statistical analysis of their study. Strict adherence to the STARD guidelines should be encouraged.
Collapse
Affiliation(s)
- Sjors F P J Coppus
- Department of Obstetrics and Gynecology, Máxima Medical Center, Veldhoven, the Netherlands.
| | | | | | | |
Collapse
|
5
|
Bry-Gauillard H, Coulondre S, Cédrin-Durnerin I, Hugues JN. [Benefits and risks of ovarian stimulation before intrauterine insemination]. GYNECOLOGIE, OBSTETRIQUE & FERTILITE 2000; 28:820-31. [PMID: 11127034 DOI: 10.1016/s1297-9589(00)00015-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Performance of intra-uterine insemination (IIU) is generally advocated as a first line therapy for infertility related to cercical hostility, male factor, unexplained infertility or mild endometriosis. IIU are usually performed following stimulation of ovulation, even in absence of anovulation. However the rationale for such a systematic ovulation induction is still questionable. Indeed, while an overall assessment of ovarian stimulation tends to conclude to a beneficial effect of these treatments in unexplained or some male infertility, it is clear that no definitive conclusion can be drawn. Indeed, the methodology in many published series is mostly inadequate, data are usually not analysed according to the type of infertility or to the female hormonal features. Finally, adverse effects are imperfectly descripted. A more accurate analysis of these data in relation to the number of recruited follicles definitively shows that, if a bifollicular development is associated with a significant increase in the pregnancy rates, there is no advantage to stimulate further the ovary. Indeed, surpassing the recruitment of two follicles would lead to dramatically increase the risk of OHSS and multiple pregnancies. Thus, further investigations including prospective, randomized studies are needed to better define what should be the most adequate regimen of ovulation induction. Specifically, tailoring the rate of multifollicular development according to the duration, the type of infertility (etiology; primary or secondary; female age) would prove to be a safer approach for getting pregnancy as well as avoiding adverse effects. Such a policy remains to be determined in the light of further clinical studies conducted in the more appropriate manner.
Collapse
Affiliation(s)
- H Bry-Gauillard
- Service de médecine de la reproduction, hôpital Jean-Verdier, assistance publique-hôpitaux de Paris, avenue du 14 juillet, université Paris XIII, 93143 Bondy, France
| | | | | | | |
Collapse
|